RE:RE:RE:RE:Global or regional partnershipsI have no Idea. Alexion is a fast growing pharma.
boehringer-ingelheim has 3 times more cash and is longer establish worldwide and of course nitedanib is their product and with 4050, they could dominate the market.
Roche is so much bigger, has much more cash, however, they would takeover Prometic so I don't think it is what managment wants.
My 2 cents woud bet on a partnership with boehringer-ingelheim. They have a worldwide sales network. They have enough money but I don't necessarely see them taking over Prometic as they are partner oriented. And of course Nintedanib and 4050 seems promising. I woud say they could be the best case scenario for Prometic.
And of course there could be ten's of different scenario so your guess is as good as mine
IMHO
Eric